IL237625D0 - Anti-mcam antibodies, compositions comprising same and uses thereof - Google Patents

Anti-mcam antibodies, compositions comprising same and uses thereof

Info

Publication number
IL237625D0
IL237625D0 IL237625A IL23762515A IL237625D0 IL 237625 D0 IL237625 D0 IL 237625D0 IL 237625 A IL237625 A IL 237625A IL 23762515 A IL23762515 A IL 23762515A IL 237625 D0 IL237625 D0 IL 237625D0
Authority
IL
Israel
Prior art keywords
compositions
anti
uses
same
mcam antibodies
Prior art date
Application number
IL237625A
Other languages
Hebrew (he)
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261698916P priority Critical
Priority to US201261797179P priority
Priority to US201261797356P priority
Priority to PCT/US2013/058773 priority patent/WO2014039975A2/en
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of IL237625D0 publication Critical patent/IL237625D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IL237625A 2012-09-10 2015-03-09 Anti-mcam antibodies, compositions comprising same and uses thereof IL237625D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US201261698916P true 2012-09-10 2012-09-10
US201261797179P true 2012-11-30 2012-11-30
US201261797356P true 2012-12-05 2012-12-05
PCT/US2013/058773 WO2014039975A2 (en) 2012-09-10 2013-09-09 Anti-mcam antibodies and associated methods of use

Publications (1)

Publication Number Publication Date
IL237625D0 true IL237625D0 (en) 2015-04-30

Family

ID=50237783

Family Applications (1)

Application Number Title Priority Date Filing Date
IL237625A IL237625D0 (en) 2012-09-10 2015-03-09 Anti-mcam antibodies, compositions comprising same and uses thereof

Country Status (23)

Country Link
US (5) US9447190B2 (en)
EP (2) EP3530287A1 (en)
JP (1) JP6339574B2 (en)
KR (1) KR20150046350A (en)
CN (2) CN107266571A (en)
AR (1) AR092488A1 (en)
AU (2) AU2013312203B2 (en)
CA (1) CA2884463A1 (en)
CL (1) CL2015000582A1 (en)
CO (1) CO7400878A2 (en)
CU (1) CU20150023A7 (en)
DK (1) DK2892562T3 (en)
EA (1) EA201590528A1 (en)
ES (1) ES2718208T3 (en)
HK (1) HK1212256A1 (en)
IL (1) IL237625D0 (en)
MX (1) MX2015002918A (en)
PE (1) PE20151286A1 (en)
PH (1) PH12015500514A1 (en)
SG (2) SG10201708127UA (en)
TW (3) TW201922795A (en)
WO (1) WO2014039975A2 (en)
ZA (1) ZA201501858B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201922795A (en) * 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 Anti-MCAM antibodies and associated methods of use
TW201623331A (en) * 2014-03-12 2016-07-01 普羅帝納生物科學公司 Anti-MCAM antibodies and associated methods of use
CA2938946A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP2017514458A (en) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Anti-laminin 4 antibody specific for LG4-5
WO2015136468A1 (en) * 2014-03-13 2015-09-17 Prothena Biosciences Limited Combination treatment for multiple sclerosis
US20170216409A1 (en) * 2014-08-05 2017-08-03 The University Of Chicago Modulation of laminin alpha-4 in the prevention, treatment, and management of metabolic syndromes
CN104725483A (en) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 Melanoma cell adhesion molecule antagonist polypeptide and application thereof
CN104710513A (en) * 2015-04-06 2015-06-17 苏州普罗达生物科技有限公司 Melanoma cell adhesion molecule antagonist polypeptide and application thereof
WO2017046774A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EP3350226A2 (en) * 2015-09-16 2018-07-25 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
AU2016366548A1 (en) * 2015-12-09 2018-06-28 Bioatla, Llc Humanized anti-CD73 antibodies
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) * 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018223140A1 (en) * 2017-06-02 2018-12-06 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 Ajinomoto Kk
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566D1 (en) 1990-01-12 2007-04-26 Amgen Fremont Inc Formation of xenogenic antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
DE69637481T2 (en) 1995-04-27 2009-04-09 Amgen Fremont Inc. Human antibodies to IL-8 derived from immunized Xenomae
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh A synergistic herbicidal mixtures
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
AU757961B2 (en) 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
AU2002354784A1 (en) 2001-07-03 2003-01-21 Sciperio, Inc. Methods and systems for embedding electrical components in a device including a frequency responsive structure
CA2441953A1 (en) * 2001-03-23 2002-10-03 The Board Of Regents Of The University Of Texas System Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
JP2005516965A (en) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド Method using anti-MUC18 antibody
AT394121T (en) 2001-12-28 2008-05-15 Amgen Fremont Inc Use of antibodies to muc18 antigen
AU2002361886A1 (en) * 2001-12-28 2003-07-24 Abgenix, Inc. Antibodies against the muc18 antigen
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7456260B2 (en) 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
EP1382615A1 (en) * 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
WO2007058725A2 (en) * 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
WO2009028663A1 (en) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. Anti-claudin-3 antibody
EP2230300A4 (en) 2007-10-24 2012-08-08 Otsuka Chemical Holdings Co Ltd Polypeptide having enhanced effector function
JP5745854B2 (en) 2007-11-13 2015-07-08 テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド Humanized antibody against TL1A
BRPI0820819A2 (en) 2007-12-21 2015-06-16 Hoffmann La Roche Antibody Formulation
US8155019B2 (en) * 2008-01-07 2012-04-10 Canon Kabushiki Kaisha Information processing apparatus, device information display method, and computer-readable storage medium
AR070141A1 (en) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Humanized antibodies specific for von Willebrand factor
US8293468B2 (en) 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof
WO2011100477A2 (en) * 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
CA2791631A1 (en) 2010-03-02 2011-09-09 Abbvie Inc. Therapeutic dll4 binding proteins
EP2601532B1 (en) 2010-08-06 2016-01-27 Mycartis N.V. Perlecan as a biomarker for renal dysfunction
EP3533803A1 (en) 2010-08-14 2019-09-04 AbbVie Inc. Amyloid-beta binding antibodies
JP5946605B2 (en) * 2011-01-28 2016-07-06 シスメックス株式会社 Method for detecting human IL-17-producing helper T cells
CA2836373A1 (en) * 2011-06-06 2012-12-13 Neotope Biosciences Limited Mcam antagonists and methods of treatment
ES2732243T3 (en) 2012-02-16 2019-11-21 Santarus Inc Pharmaceutical compositions of ANTI-VLA1 antibodies (CD49A)
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
TW201922795A (en) * 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 Anti-MCAM antibodies and associated methods of use
CA2926089A1 (en) 2013-10-24 2015-04-30 Medimmune, Llc Stable, aqueous antibody formulations
WO2015136570A1 (en) 2014-03-11 2015-09-17 パナソニック液晶ディスプレイ株式会社 Display device and driving method therefor
US20170129954A1 (en) 2014-03-12 2017-05-11 Prothena Biosciences Limited Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
JP2017514458A (en) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Anti-laminin 4 antibody specific for LG4-5
CA2938946A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
TW201623331A (en) 2014-03-12 2016-07-01 普羅帝納生物科學公司 Anti-MCAM antibodies and associated methods of use
JP2017512772A (en) 2014-03-12 2017-05-25 プロセナ バイオサイエンシーズ リミテッド Anti-laminin 4 antibody specific for LG1-3
US20170101470A1 (en) 2014-03-12 2017-04-13 Prothena Biosciences Limited Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
WO2015136468A1 (en) 2014-03-13 2015-09-17 Prothena Biosciences Limited Combination treatment for multiple sclerosis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EP3350226A2 (en) 2015-09-16 2018-07-25 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018223140A1 (en) 2017-06-02 2018-12-06 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Also Published As

Publication number Publication date
AU2013312203A1 (en) 2015-03-19
CN107266571A (en) 2017-10-20
TW201809001A (en) 2018-03-16
PH12015500514A1 (en) 2015-04-27
AU2013312203B2 (en) 2018-07-12
US10414825B2 (en) 2019-09-17
CA2884463A1 (en) 2014-03-13
PE20151286A1 (en) 2015-10-04
ES2718208T3 (en) 2019-06-28
EP3530287A1 (en) 2019-08-28
KR20150046350A (en) 2015-04-29
SG10201708127UA (en) 2017-11-29
US10407507B2 (en) 2019-09-10
JP2015533795A (en) 2015-11-26
EA201590528A1 (en) 2015-12-30
WO2014039975A3 (en) 2014-06-05
AR092488A1 (en) 2015-04-22
TWI595007B (en) 2017-08-11
EP2892562A4 (en) 2016-05-04
CO7400878A2 (en) 2015-09-30
TW201922795A (en) 2019-06-16
US9447190B2 (en) 2016-09-20
WO2014039975A2 (en) 2014-03-13
CN105120895A (en) 2015-12-02
ZA201501858B (en) 2016-11-30
TW201422639A (en) 2014-06-16
SG11201501773RA (en) 2015-04-29
CU20150023A7 (en) 2016-03-31
US20140227292A1 (en) 2014-08-14
EP2892562A2 (en) 2015-07-15
MX2015002918A (en) 2015-08-14
DK2892562T3 (en) 2019-04-15
JP6339574B2 (en) 2018-06-06
EP2892562B1 (en) 2019-03-06
AU2018241135A1 (en) 2018-10-25
US20170145109A1 (en) 2017-05-25
US20180105602A1 (en) 2018-04-19
CL2015000582A1 (en) 2015-11-06
TWI660972B (en) 2019-06-01
US20150239980A1 (en) 2015-08-27
US20170037144A1 (en) 2017-02-09
HK1212256A1 (en) 2016-06-10

Similar Documents

Publication Publication Date Title
IL227963A (en) Cytotxic benzodiazepine derivatives, compositions comprising the same and uses thereof
EP2885418A4 (en) Microcapsule compositions and methods
HK1206388A1 (en) Crispr-cas component systems, methods and compositions for sequence manipulation crispr-cas
SG11201500093TA (en) Immunoconjugates comprising anti-cd79b antibodies
EP2849790A4 (en) Drug-conjugates, conjugation methods, and uses thereof
GB2499921B (en) Biophotonic compositions, kits and methods
IL233154A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
PT2560653T (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
FR3000096B1 (en) Composition comprising 2,3,3,3-tetrafluoropropene
GB201115529D0 (en) Antibodies, uses and methods
IL233934D0 (en) Cd47 antibodies, compositions comprising the same and uses thereof
IL252063A (en) Dna-pk inhibitors, compositions comprising same and uses thereof
EP2560488A4 (en) Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2838954A4 (en) Adhesive compositions and methods
IL222465D0 (en) Certain amino-pyridazines, compositions thereof, and methods for their use
IL238958D0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
HK1205751A1 (en) Conjugates, particles, compositions, and related methods
IL236348D0 (en) Anti-jagged antibodies, compositions comprising the same and uses thereof
EP2888238A4 (en) Benzocyclooctyne compounds and uses thereof
EP2836212A4 (en) Novel compositions and methods
EP2872641A4 (en) Biorefinery system, methods and compositions thereof
IL238959A (en) Glutamase inhibitors, compositions comprising same and uses thereof
IL243752D0 (en) Multispecific antibodies, compositions comprising same and uses thereof
FR3000095B1 (en) Composition comprising 2,3,3,3-tetrafluoropropene and 1,2-difluoroethylene
IL235767A (en) Substituted pyrrolidines, pharmaceutical compositions comprising the same and uses thereof